Inhibition of Poly(ADP-ribose) Polymerase Sensitizes [ 177 Lu]Lu-DOTAGA.(SA.FAPi) 2 -Mediated Radiotherapy in Triple-Negative Breast Cancer
Molecular Pharmaceutics · 2023
DOI: 10.1021/acs.molpharmaceut.2c01051 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Guangfa Bao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan 43…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Fibroblast activation protein (FAP) is highly expressed in many tumor types and constitutes a promising target for tumor-specific delivery of therapeutic radionuclides. [177Lu]Lu-DOTAGA.(SA.FAPi)2 is a novel radiopharmaceutical based on a novel bidentate inhibitor of FAP that is excreted more slowly than its monomeric counterparts. Still, the efficacy of radiotherapy is mitigated by cascades of DNA damage repair signaling in tumor cells including those via Poly(ADP-ribose) polymerase (PARP). We hereby aimed to evaluate the efficacy of [177Lu]Lu-DOTAGA.(SA.FAPi)2 in combination with a PARP inhibitor, Olaparib, in the 4T1 murine triple negative breast cancer (TNBC) model. The therapeutic efficacy was visualized using 18F-FDG and [68Ga]Ga-FAPI-04 positron emission imaging/computer tomography (PET/CT). Our results demonstrated that Olaparib suppressed BALB/3T3 fibroblasts in vitro and sensitized the efficacy of [177Lu]Lu-DOTAGA.(SA.FAPi)2 in mice bearing 4T1 tumors via enhancement of DNA damage. Treatment-associated toxicity was tolerable with only mild leukopenia. Therefore, the combination of [177Lu]Lu-DOTAGA.(SA.FAPi)2 and Olaparib is a feasible treatment against TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan 430074, China.
- Department of Chemistry, Johannes Gutenberg University, 55131 Mainz, Germany.
- Department of Anatomy, School of Basic Medicine, Huazhong University of Science and Technology, Hubei Province, Wuhan 430030, China.
- Cell Architecture Research Center, Huazhong University of Science and Technology, Hubei Province, Wuhan 430030, China.
ORCID-Profile: Huimin Zhou, Jun Zhao, Xiaohua Zhu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Bao, G., Zhou, H., Zou, S., Chen, L., Zhang, B., Wang, Z., Moon, E. S., Zhao, J., Roesch, F., & Zhu, X. (2023). Inhibition of Poly(ADP-ribose) Polymerase Sensitizes [ 177 Lu]Lu-DOTAGA.(SA.FAPi) 2 -Mediated Radiotherapy in Triple-Negative Breast Cancer. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.2c01051
Vancouver
Bao G, Zhou H, Zou S, Chen L, Zhang B, Wang Z, et al. Inhibition of Poly(ADP-ribose) Polymerase Sensitizes [ 177 Lu]Lu-DOTAGA.(SA.FAPi) 2 -Mediated Radiotherapy in Triple-Negative Breast Cancer. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.2c01051
BibTeX
@article{Bao2023,
author = {Bao, Guangfa and Zhou, Huimin and Zou, Sijuan and Chen, Lixing and Zhang, Buchuan and Wang, Ziqiang and Moon, Euy Sung and Zhao, Jun and Roesch, Frank and Zhu, Xiaohua},
title = {Inhibition of Poly(ADP-ribose) Polymerase Sensitizes [ 177 Lu]Lu-DOTAGA.(SA.FAPi) 2 -Mediated Radiotherapy in Triple-Negative Breast Cancer},
journal = {Molecular Pharmaceutics},
year = {2023},
doi = {10.1021/acs.molpharmaceut.2c01051}
}
EUVIMED